Viro Chem Pharma, Inc.

Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals (Canada) Incorporated

Biochem Pharma Inc.

Laval Chan Chun Kong

Sanjoy Kumar Das

Carl Poisson

Oswy Z Pereira

Constantin G Yannopoulos

Louis Vaillancourt

Thumkunta Jagadeeswar Reddy

Christophe Moinet

Marc Courchesne

Monica Bubenik

Nghe Nguyen-Ba

Guy Falardeau

Real Denis

Liliane Halab

Mohammad Arshad Siddiqui

Caroline Cadilhac

Wuyi Wang

Jean Bedard

Melanie Proulx

John Patrick Maxwell

Simon Giroux

Mark A Morris

James A Henderson

Bingcan Liu

Rabindra Rej

T Jagadeeswar Reddy

Nghe Nguyen Ba

Irina Motorina

Jian Jim Wang

Albert Charles Pierce

Kevin Michael Cottrell

Govinda Rao Bhisetti

Ronald Lee Grey, Jr

Valerie Marone

Réal Denis

Charles Blais

Nathalie Chauret

Zhang Ming-Qiang

Bettina Hamelin

Constanin Yannopoulos

Ming-Qiang Zhang

Youssef L Bennani

Gervais Dionne

William L Brown

Youssef Laafiret Bennani

Mingqiang Zhang

Miguel Quimpere

Paul Nguyen-Ba

Nathalie Turcotte

Thunkunta Jagadeeswar Reddy

Ming Qiang Zhang

Youssef L Benanni

Stephen Joseph Shuttleworth

Bingan Liu

Mélanie Proulx

Compounds represented by formula: Wherein X, Y and Z are as defined herein, pharmaceutically acceptable salts thereof, and related compounds, are suitable for use in treating or preventing a Flaviviridae viral infection in a host.

[object Object]

Compounds represented by formula I or pharmaceutically acceptable salts thereof, wherein A, B, B', X, Y, R, R, R&#x2032;, R, R&#x2032;, R, R&#x2032;, R, R&#x2032;, m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.

Analogues for the treatment or prevention of flavivirus infections

Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein A, B, B', X, Y, R, R&#x2032;, R, R&#x2032;, R, R&#x2032;, R, R&#x2032;, R, m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.

Benzimidazole analogues for the treatment or prevention of flavivirus infections

Compounds and methods for the treatment or prevention of flavivirus infections

Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein R, X, Y, and Z are as defined herein, are useful for treating flaviviridae viral infections.

Thiophene analogues for the treatment or prevention of flavivirus infections

The invention relates to 21-keto triterpene compounds of formula (I): wherein R, X and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infections by administering therapeutically effective amounts of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof to a subject in need of such treatment.

C-21-keto lupane derivatives preparation and use thereof

Compounds represented by formula: wherein X, Y and Z are as defined herein, pharmaceutically acceptable salts thereof, and related compounds, are suitable for use in treating or preventing a Flaviviridae viral infection in a host.

The present invention provides novel compounds represented by formula I: or pharmaceutically acceptable salts thereof useful for treating flaviviridae viral infection.

The invention relates to 21-keto triterpene compounds of formula (I): wherein R, X, and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infections by administering therapeutically effective amounts of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof to a subject in need of such treatment. 

Lupane derivatives useful for treating HIV

Compounds according to formula (I): wherein R, R, R, n and X are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity. Additionally, compounds according to Formula III: wherein Z, R', and R&#x2032;are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful as intermediates for production of compounds that modulate CCR5 chemokine receptor activity.

Spirotropane compounds

Compounds according to formula (I): wherein A, Rand Rare as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof are useful for the modulation of CCR5 chemokine receptor activity.

Spirotropane compounds and methods for the modulation of chemokine receptor activity

Growing community of inventors

Kirkland, Canada

Laval Chan Chun Kong